U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
SAN DIEGO, May 08, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 15, 2017 at 5:00 p.m. ET to report its first quarter 2017 financial results and provide a corporate update.
In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 18632775. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
